Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

November 2025

Clinical efficacy, drug retention and recurrence of ixekizumab across psoriasis severities: A multicenter retrospective analysis of 354 patients

J Dermatol Treat 2025;36:2562299 Doi: 10.1080/09546634.2025.2562299

Qiao Z,

Chai B,

Chen Y,

Jin HZ,

Yang B,

Li F,

Shi Y,

Gu J,

Guo Q,

Wu L,

Lu T,

Dang L,

Kang X,

Liu X

Qiao et al. showed that ixekizumab demonstrated superior efficacy in mild-moderate versus severe PsO, suggesting greater benefit with early biologic intervention. Authors compared clinical efficacy, relapse rates, and drug retention between mild-to-moderate and severe plaque PsO cohorts with different severity levels treated with Ixekizumab.

Keywords:

July 2025

A randomized Phase II study of efmarodocokin alfa, an interleukin-22 agonist, versus vedolizumab in patients with ulcerative colitis

Clinical Gastroenterology and Hepatology 2025;23:1387–1397 doi: 10.1016/j.cgh.2024.11.013

Danese S,

Rothenberg ME,

Lim JJ,

Ding,

HTMcBride JM,

Chen Y,

Dash A,

Mar JS,

Keir M,

Panes J,

Danese et al. observed that efmarodocokin alfa did not demonstrate efficacy compared to the PBO, and this Phase II study ended early for futility; however, there was evidence of target engagement (skin AEs, regenerating islet derived protein 3-alpha).

Keywords:

May 2025

Cardiovascular disease risk in patients with psoriasis receiving biologics targeting TNF-α, IL-12/23, IL-17, and IL-23: A population-based retrospective cohort study

PLoS Med 22(4): e1004591 DOI: org/10.1371/journal.pmed.1004591

Lin TI,

Fan YH,

Fan KS,

Juan CK,

Chen YJ,

Wu CY

Lin et al. compared the risk of CVD in patients with psoriasis who were prescribed biologics or oral therapies and assessed the association between different classes of biologics and CVD risk. Patients with psoriasis-prescribed biologics exhibited a reduced risk of incident CVDs compared with those receiving oral antipsoriatic drugs.